PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation,
safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be
given to all patients who participate. Stratum I will determine the maximum tolerated dose
and any dose-limiting toxicities. The second part (Stratum II) is a prospectively randomized,
multi-center, double-masked, dose ranging study evaluating the efficacy and safety of
PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in patients
with DME.